Zofia Botto
Zofia Botto has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Reizer
Medical Center in Łańcut, Łańcut, Poland
8 shared publications - Dominik Andrzej Ślazyk
The University Hospital in Krakow, Krakow, Poland
8 shared publications - Dominika Kowalczyk
Private practice, Dębica, Poland
8 shared publications - Klaudia Krystek
Private Practice, Krakow, Poland
8 shared publications - Patrycja Felisiak
Medical University of Lublin, Lublin, Poland
8 shared publications - Zofia Śliwa
Independent Researcher, Warsaw, Poland
8 shared publications
Latest Publications
- Open Access
- 24 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (1(49))
DIGITAL DEMENTIA IN CHILDREN AND ADOLESCENTS: SYMPTOMS, RISK FACTORS AND PREVENTION STRATEGIES. A NARRATIVE REVIEW
Children and adolescents, as the new generation of avid technology users, are often able to use it to their great benefit. However, it comes with the cost of being exposed to a variety of health risks, cognitive health being one of the main areas affected. As developing brains are the most susceptible to these risks, Manfred Spitzer’s concept of digital dementia seems as relevant as ever nowadays. In the present study, we analyse over a hundred published works with the goal of creating a compact yet comprehensive summary of existing knowledge on digital dementia in the population of infants, preschoolers, schoolchildren and adolescents. Findings suggest that multiple cognition areas are affected, with memory, critical thinking and problem solving being among the most alarming. While the role of parents as guardians of digital health cannot be overstated, other factors such as environment and unmodifiable traits also play a role. For preventing and mitigating this problem, a collaborative effort of caretakers but also teachers, doctors and policy makers is most urgently needed. We conclude that digital dementia among youth is a common problem, therefore recognising symptoms early, minimising risks and preventing its progression will prove beneficial to whole generations.
- 24 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (1(49))
Open AccessDIGITAL DEMENTIA IN CHILDREN AND ADOLESCENTS: SYMPTOMS, RISK FACTORS AND PREVENTION STRATEGIES. A NARRATIVE REVIEW
Children and adolescents, as the new generation of avid technology users, are often able to use it to their great benefit. However, it comes with the cost of being exposed to a variety of health risks, cognitive health being one of the main areas affected. As developing brains are the most susceptible to these risks, Manfred Spitzer’s concept of digital dementia seems as relevant as ever nowadays. In the present study, we analyse over a hundred published works with the goal of creating a compact yet comprehensive summary of existing knowledge on digital dementia in the population of infants, preschoolers, schoolchildren and adolescents. Findings suggest that multiple cognition areas are affected, with memory, critical thinking and problem solving being among the most alarming. While the role of parents as guardians of digital health cannot be overstated, other factors such as environment and unmodifiable traits also play a role. For preventing and mitigating this problem, a collaborative effort of caretakers but also teachers, doctors and policy makers is most urgently needed. We conclude that digital dementia among youth is a common problem, therefore recognising symptoms early, minimising risks and preventing its progression will prove beneficial to whole generations.
- Open Access
- 23 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
SHRINKING LUNG SYNDROME IN SYSTEMIC LUPUS ERYTHEMATOSUS-CLINICAL AND THERAPEUTIC CHALLENGES
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. One of its rare but clinically significant complications is the shrinking lung syndrome (SLS), which affects less than 1% of patients and presents diagnostic and therapeutic challenges. Aim: This paper aims to present a comprehensive overview of shrinking lung syndrome as a rare manifestation of SLE, with a focus on its pathophysiology, diagnostic difficulties, and current therapeutic approaches. Materials and Methods: A narrative review was conducted based on selected scientific publications indexed in PubMed, Scopus, and Google Scholar. The inclusion criteria included articles describing the pathophysiology, clinical features, diagnosis, and treatment of SLS in the context of SLE. Results: SLS is characterized by progressive dyspnea, diaphragmatic elevation, and restrictive defects on pulmonary function testing. The exact pathogenesis remains unclear but involves neuromuscular dysfunction, diaphragmatic weakness, pleural involvement, and potential autoantibody-mediated mechanisms. Diagnosis is challenging due to the absence of specific markers and requires exclusion of other causes. Treatment primarily includes corticosteroids and immunosuppressants, with adjunctive respiratory rehabilitation. Despite therapy, pulmonary restriction may persist. Conclusions: SLS remains an under-recognized and underdiagnosed complication of SLE. Increased clinical awareness and early diagnostic interventions are key to preventing long-term respiratory impairment. Future research is needed to establish standardized diagnostic protocols and treatment guidelines.
- 23 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
Open AccessSHRINKING LUNG SYNDROME IN SYSTEMIC LUPUS ERYTHEMATOSUS-CLINICAL AND THERAPEUTIC CHALLENGES
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. One of its rare but clinically significant complications is the shrinking lung syndrome (SLS), which affects less than 1% of patients and presents diagnostic and therapeutic challenges. Aim: This paper aims to present a comprehensive overview of shrinking lung syndrome as a rare manifestation of SLE, with a focus on its pathophysiology, diagnostic difficulties, and current therapeutic approaches. Materials and Methods: A narrative review was conducted based on selected scientific publications indexed in PubMed, Scopus, and Google Scholar. The inclusion criteria included articles describing the pathophysiology, clinical features, diagnosis, and treatment of SLS in the context of SLE. Results: SLS is characterized by progressive dyspnea, diaphragmatic elevation, and restrictive defects on pulmonary function testing. The exact pathogenesis remains unclear but involves neuromuscular dysfunction, diaphragmatic weakness, pleural involvement, and potential autoantibody-mediated mechanisms. Diagnosis is challenging due to the absence of specific markers and requires exclusion of other causes. Treatment primarily includes corticosteroids and immunosuppressants, with adjunctive respiratory rehabilitation. Despite therapy, pulmonary restriction may persist. Conclusions: SLS remains an under-recognized and underdiagnosed complication of SLE. Increased clinical awareness and early diagnostic interventions are key to preventing long-term respiratory impairment. Future research is needed to establish standardized diagnostic protocols and treatment guidelines.
- Open Access
- 15 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 88
Semaglutide-Induced Weight Loss: Consequences for Muscle Mass and Functional Outcomes
Introduction: Semaglutide (Ozempic) is a long-acting GLP-1 receptor agonist used in the treatment of type 2 diabetes and obesity. Its potent effects on appetite suppression, delayed gastric emptying, and weight reduction are well documented. Increasing scientific attention has focused on its potential influence on lean body mass and skeletal muscle, as emerging evidence suggests that semaglutide-induced weight loss may include clinically relevant reductions in muscle mass. Understanding the extent and significance of these changes is essential for safe long-term therapy. Material and Methods of Research: A literature review was conducted using PubMed, Google Scholar, and Scopus. Clinical trials, observational studies, meta-analyses, and relevant preclinical research published in English between 2018 and 2024 were analyzed. Results:Evidence indicates that semaglutide-induced weight loss consistently leads to reductions in lean mass, typically comprising 20–40% of total weight lost. Mechanisms include caloric deficit, reduced protein intake, appetite suppression, and changes in anabolic signalin. Several studies demonstrated preserved muscle strength or stabilization of lean mass when therapy was combined with adequate protein intake and resistance training. Preclinical findings suggest that part of the lean mass reduction is reversible after treatment discontinuation. Conclusion: Semaglutide affects muscle mass primarily indirectly through appetite suppression and significant weight reduction. While lean mass loss is common, functional muscle decline is not inevitable and may be mitigated through dietary optimization and structured physical activity. Regular monitoring of body composition should be considered during semaglutide therapy.
- 15 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 88
Open AccessSemaglutide-Induced Weight Loss: Consequences for Muscle Mass and Functional Outcomes
Introduction: Semaglutide (Ozempic) is a long-acting GLP-1 receptor agonist used in the treatment of type 2 diabetes and obesity. Its potent effects on appetite suppression, delayed gastric emptying, and weight reduction are well documented. Increasing scientific attention has focused on its potential influence on lean body mass and skeletal muscle, as emerging evidence suggests that semaglutide-induced weight loss may include clinically relevant reductions in muscle mass. Understanding the extent and significance of these changes is essential for safe long-term therapy. Material and Methods of Research: A literature review was conducted using PubMed, Google Scholar, and Scopus. Clinical trials, observational studies, meta-analyses, and relevant preclinical research published in English between 2018 and 2024 were analyzed. Results:Evidence indicates that semaglutide-induced weight loss consistently leads to reductions in lean mass, typically comprising 20–40% of total weight lost. Mechanisms include caloric deficit, reduced protein intake, appetite suppression, and changes in anabolic signalin. Several studies demonstrated preserved muscle strength or stabilization of lean mass when therapy was combined with adequate protein intake and resistance training. Preclinical findings suggest that part of the lean mass reduction is reversible after treatment discontinuation. Conclusion: Semaglutide affects muscle mass primarily indirectly through appetite suppression and significant weight reduction. While lean mass loss is common, functional muscle decline is not inevitable and may be mitigated through dietary optimization and structured physical activity. Regular monitoring of body composition should be considered during semaglutide therapy.
- Open Access
- 31 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Reformer Pilates vs Mat Pilates and Muscle Mass: Current State of Knowledge
Pilates is widely implemented in sport, rehabilitation, and health-oriented exercise programs, with well-documented benefits for strength, flexibility, balance, and functional performance. However, its effectiveness in inducing skeletal muscle hypertrophy remains uncertain. This narrative review summarizes and critically evaluates the current state of knowledge regarding the effects of mat-based and reformer-based Pilates on muscle mass–related outcomes. Evidence from randomized controlled trials, comparative studies, and systematic reviews examining lean body mass, fat-free mass, appendicular lean mass, or muscle size was synthesized. Available findings indicate that clinically meaningful increases in muscle mass following Pilates training are inconsistent across populations and study designs. Mat Pilates generally demonstrates minimal effects on lean mass, while reformer Pilates is mechanistically better positioned to promote hypertrophy due to its capacity for external loading and progression; nevertheless, empirical support for this effect remains limited and heterogeneous. Overall, Pilates reliably improves strength and functional outcomes but does not consistently elicit robust muscle mass gains. Reformer Pilates may offer advantages over mat Pilates for muscle mass accretion when progressive resistance is emphasized, although further high-quality, hypertrophy-focused trials are required to clarify its role.
- 31 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Open AccessReformer Pilates vs Mat Pilates and Muscle Mass: Current State of Knowledge
Pilates is widely implemented in sport, rehabilitation, and health-oriented exercise programs, with well-documented benefits for strength, flexibility, balance, and functional performance. However, its effectiveness in inducing skeletal muscle hypertrophy remains uncertain. This narrative review summarizes and critically evaluates the current state of knowledge regarding the effects of mat-based and reformer-based Pilates on muscle mass–related outcomes. Evidence from randomized controlled trials, comparative studies, and systematic reviews examining lean body mass, fat-free mass, appendicular lean mass, or muscle size was synthesized. Available findings indicate that clinically meaningful increases in muscle mass following Pilates training are inconsistent across populations and study designs. Mat Pilates generally demonstrates minimal effects on lean mass, while reformer Pilates is mechanistically better positioned to promote hypertrophy due to its capacity for external loading and progression; nevertheless, empirical support for this effect remains limited and heterogeneous. Overall, Pilates reliably improves strength and functional outcomes but does not consistently elicit robust muscle mass gains. Reformer Pilates may offer advantages over mat Pilates for muscle mass accretion when progressive resistance is emphasized, although further high-quality, hypertrophy-focused trials are required to clarify its role.
- Open Access
- 27 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Comprehensive Analysis of Therapeutic Strategies for Mycoplasma pneumoniae Infections: A Global and European Review of Current Antibiotic Treatment Standards in Paediatric and Adult Populations in an Era of Increasing Antimicrobial Resistance
Background.Mycoplasma pneumoniae infections remain a significant clinical challenge, particularly in the paediatric population, where they constitute a common cause of community-acquired pneumonia (CAP). The absence of a cell wall results in intrinsic resistance to beta-lactam antibiotics, necessitating the use of antimicrobials targeting intracellular processes. In the post-pandemic period, a resurgence of M. pneumoniae infections has been observed, partly attributed to an “immunity gap” following non-pharmaceutical interventions. At the same time, macrolide-resistant M. pneumoniae (MRMP) has become an increasing concern, especially in Asia and increasingly in Europe, significantly influencing therapeutic strategies. Aim.To review current antibiotic treatment standards for Mycoplasma pneumoniae infections in children and adults, with particular emphasis on macrolide resistance, regional epidemiology, and practical clinical management of CAP of suspected mycoplasmal aetiology. Material and methods.This narrative review analysed contemporary literature published primarily between 2010 and 2025. Data sources included clinical guidelines for CAP in adults and children, systematic reviews and meta-analyses on MRMP, primary studies on resistance mechanisms (23S rRNA mutations, L4/L22 alterations, resistance emergence during therapy), and studies evaluating doxycycline safety in children. Peer-reviewed articles indexed in PubMed and PubMed Central were included. The synthesis was structured according to patient age, disease severity, geographical region, and therapeutic decision pathways. Results.Available evidence indicates increasing global prevalence of MRMP, with marked regional differences. Macrolides remain first-line therapy in many settings; however, treatment failure rates are higher in regions with elevated resistance. Doxycycline and fluoroquinolones represent effective alternatives, with growing evidence supporting doxycycline safety in paediatric populations. Escalation of therapy after 48–72 hours of non-response is a key component of effective management, particularly in severe or refractory cases. Conclusions.Mycoplasma pneumoniae remains a major cause of CAP in both children and adults. Rising macrolide resistance necessitates region-specific treatment strategies, careful clinical reassessment, and judicious antibiotic selection. Updated management algorithms incorporating resistance patterns and timely therapy escalation are essential to optimise outcomes and support antibiotic stewardship.
- 27 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Open AccessComprehensive Analysis of Therapeutic Strategies for Mycoplasma pneumoniae Infections: A Global and European Review of Current Antibiotic Treatment Standards in Paediatric and Adult Populations in an Era of Increasing Antimicrobial Resistance
Background.Mycoplasma pneumoniae infections remain a significant clinical challenge, particularly in the paediatric population, where they constitute a common cause of community-acquired pneumonia (CAP). The absence of a cell wall results in intrinsic resistance to beta-lactam antibiotics, necessitating the use of antimicrobials targeting intracellular processes. In the post-pandemic period, a resurgence of M. pneumoniae infections has been observed, partly attributed to an “immunity gap” following non-pharmaceutical interventions. At the same time, macrolide-resistant M. pneumoniae (MRMP) has become an increasing concern, especially in Asia and increasingly in Europe, significantly influencing therapeutic strategies. Aim.To review current antibiotic treatment standards for Mycoplasma pneumoniae infections in children and adults, with particular emphasis on macrolide resistance, regional epidemiology, and practical clinical management of CAP of suspected mycoplasmal aetiology. Material and methods.This narrative review analysed contemporary literature published primarily between 2010 and 2025. Data sources included clinical guidelines for CAP in adults and children, systematic reviews and meta-analyses on MRMP, primary studies on resistance mechanisms (23S rRNA mutations, L4/L22 alterations, resistance emergence during therapy), and studies evaluating doxycycline safety in children. Peer-reviewed articles indexed in PubMed and PubMed Central were included. The synthesis was structured according to patient age, disease severity, geographical region, and therapeutic decision pathways. Results.Available evidence indicates increasing global prevalence of MRMP, with marked regional differences. Macrolides remain first-line therapy in many settings; however, treatment failure rates are higher in regions with elevated resistance. Doxycycline and fluoroquinolones represent effective alternatives, with growing evidence supporting doxycycline safety in paediatric populations. Escalation of therapy after 48–72 hours of non-response is a key component of effective management, particularly in severe or refractory cases. Conclusions.Mycoplasma pneumoniae remains a major cause of CAP in both children and adults. Rising macrolide resistance necessitates region-specific treatment strategies, careful clinical reassessment, and judicious antibiotic selection. Updated management algorithms incorporating resistance patterns and timely therapy escalation are essential to optimise outcomes and support antibiotic stewardship.
- Open Access
- 22 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Aerobic Exercise as an Essential Component of Non-Pharmacological Management for Metabolic Syndrome - A Review
Background. Metabolic Syndrome (MetS) is a prevalent cluster of conditions that significantly increases the risk of cardiovascular disease and type 2 diabetes mellitus. Lifestyle modification is universally recognized as the primary therapeutic strategy, with aerobic exercise playing a crucial role in improving metabolic health and reducing mortality risks in affected populations. Aim. This review synthesizes current evidence on the efficacy and mechanisms of aerobic exercise as a fundamental non-pharmacological strategy for managing Metabolic Syndrome (MetS). Material and methods. A search of major databases (2015–2025) was performed, focusing on systematic reviews and RCTs. Keywords included "Metabolic Syndrome," "aerobic exercise," "insulin resistance," "dyslipidemia," and "exercise prescription." Results. Regular aerobic exercise improves cardiometabolic risk factors independently of significant weight loss. It enhances insulin sensitivity via GLUT4 translocation, optimizes the lipid profile (reducing triglycerides, increasing HDL), and reduces visceral adiposity and inflammation. Additionally, High-Intensity Interval Training (HIIT) is highlighted as a potent strategy, often offering superior efficacy to moderate-intensity continuous training (MICT). Conclusions. Aerobic exercise is an essential component of MetS management. Professionals should prioritize individualized prescriptions, incorporating both MICT and HIIT, to effectively mitigate cardiometabolic risk and improve patient health.
- 22 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Open AccessAerobic Exercise as an Essential Component of Non-Pharmacological Management for Metabolic Syndrome - A Review
Background. Metabolic Syndrome (MetS) is a prevalent cluster of conditions that significantly increases the risk of cardiovascular disease and type 2 diabetes mellitus. Lifestyle modification is universally recognized as the primary therapeutic strategy, with aerobic exercise playing a crucial role in improving metabolic health and reducing mortality risks in affected populations. Aim. This review synthesizes current evidence on the efficacy and mechanisms of aerobic exercise as a fundamental non-pharmacological strategy for managing Metabolic Syndrome (MetS). Material and methods. A search of major databases (2015–2025) was performed, focusing on systematic reviews and RCTs. Keywords included "Metabolic Syndrome," "aerobic exercise," "insulin resistance," "dyslipidemia," and "exercise prescription." Results. Regular aerobic exercise improves cardiometabolic risk factors independently of significant weight loss. It enhances insulin sensitivity via GLUT4 translocation, optimizes the lipid profile (reducing triglycerides, increasing HDL), and reduces visceral adiposity and inflammation. Additionally, High-Intensity Interval Training (HIIT) is highlighted as a potent strategy, often offering superior efficacy to moderate-intensity continuous training (MICT). Conclusions. Aerobic exercise is an essential component of MetS management. Professionals should prioritize individualized prescriptions, incorporating both MICT and HIIT, to effectively mitigate cardiometabolic risk and improve patient health.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
AN AGE-OLD PROBLEM IN A HIGH-TECH WORLD: THE DIGITAL HEALTH CARE DIVIDE FOR ELDERLY PATIENTS
The rapid digitalization of health care, propelled by the COVID-19 pandemic, has led to a rapidly growing gap in use of medical technology for senior patients. The inclusion of wearable medical devices, patient portals, telemedicine, and access to information has created an opportunity for patients to have more control over their health than ever before. However, for elderly patients it also comes with new challenges due to fear or reluctance to use advanced technologies they are not familiar with, leaving them to rely on family members and caregivers. It was found that health care provider’s hesitation in offering digital options and the expenses associated with digital devices are another obstacle. There is a significant need for modification in health care personnel attitudes regarding technology, promotion of combining community centers and health care for improving overall quality of life and digital literacy, and advocacy for senior patients' opinions when creating new medical technology and possibly incorporating AI technology to aid in bridging the gap.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessAN AGE-OLD PROBLEM IN A HIGH-TECH WORLD: THE DIGITAL HEALTH CARE DIVIDE FOR ELDERLY PATIENTS
The rapid digitalization of health care, propelled by the COVID-19 pandemic, has led to a rapidly growing gap in use of medical technology for senior patients. The inclusion of wearable medical devices, patient portals, telemedicine, and access to information has created an opportunity for patients to have more control over their health than ever before. However, for elderly patients it also comes with new challenges due to fear or reluctance to use advanced technologies they are not familiar with, leaving them to rely on family members and caregivers. It was found that health care provider’s hesitation in offering digital options and the expenses associated with digital devices are another obstacle. There is a significant need for modification in health care personnel attitudes regarding technology, promotion of combining community centers and health care for improving overall quality of life and digital literacy, and advocacy for senior patients' opinions when creating new medical technology and possibly incorporating AI technology to aid in bridging the gap.
- Open Access
- 25 December 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 48
The use of high-intensity interval training (HIIT) in cardiac rehabilitation - a review
Background. Cardiac rehabilitation plays a crucial role in reducing mortality and improving the quality of life in patients after cardiovascular events. High-intensity interval training (HIIT) is gaining attention as a time-efficient and potentially more effective alternative to moderate-intensity continuous training (MICT). Aim. The aim of this review is to assess the effectiveness and the safety of high-intensity interval training in cardiac rehabilitation. Material and methods. A literature search was performed using PubMed database, narrowing it down to studies published between 2015 and 2025. The inclusion criteria focused on the use of high-intensity interval training in patients with coronary artery disease, after myocardial infarction, and with heart failure. Results. The analyzed studies demonstrated that high-intensity interval training significantly improves cardiorespiratory fitness, endothelial function, and metabolic parameters. Recent meta-analyses confirm the effectiveness of HIIT showing a significantly greater increase in peak oxygen uptake (VO₂ peak), with an average difference of approximately 1.42 mL/kg/min, compared to MICT. When patients are properly selected and monitored, HIIT is safe and well tolerated in cardiac rehabilitation programs. Conclusions. HIIT is an effective and safe form of exercise for cardiac patients and may complement or even replace traditional training approaches. However, it requires individualized programming and supervision by a specialized medical team. Further research is necessary to confirm its long-term outcomes.
- 25 December 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 48
Open AccessThe use of high-intensity interval training (HIIT) in cardiac rehabilitation - a review
Background. Cardiac rehabilitation plays a crucial role in reducing mortality and improving the quality of life in patients after cardiovascular events. High-intensity interval training (HIIT) is gaining attention as a time-efficient and potentially more effective alternative to moderate-intensity continuous training (MICT). Aim. The aim of this review is to assess the effectiveness and the safety of high-intensity interval training in cardiac rehabilitation. Material and methods. A literature search was performed using PubMed database, narrowing it down to studies published between 2015 and 2025. The inclusion criteria focused on the use of high-intensity interval training in patients with coronary artery disease, after myocardial infarction, and with heart failure. Results. The analyzed studies demonstrated that high-intensity interval training significantly improves cardiorespiratory fitness, endothelial function, and metabolic parameters. Recent meta-analyses confirm the effectiveness of HIIT showing a significantly greater increase in peak oxygen uptake (VO₂ peak), with an average difference of approximately 1.42 mL/kg/min, compared to MICT. When patients are properly selected and monitored, HIIT is safe and well tolerated in cardiac rehabilitation programs. Conclusions. HIIT is an effective and safe form of exercise for cardiac patients and may complement or even replace traditional training approaches. However, it requires individualized programming and supervision by a specialized medical team. Further research is necessary to confirm its long-term outcomes.